Recently, the research paper titled "Development of highly bioactive long-acting recombinant porcine FSH for batch production management of sows" by Professor Luo Haoshu's team, the founder and chief scientist of VJTBio, was published in the international authoritative academic journal Scientific Reports. This study utilized CHO cells to express the recombinant long-acting porcine follicle-stimulating hormone fusion protein, demonstrated the biological activity of the recombinant fusion protein in the model animal mice, and conducted pharmacokinetic detection in rats and pigs, proving the long-acting nature of the fusion protein. Undoubtedly, this study represents a novel and breakthrough product in the field of pig reproduction. It breaks the limitations of traditional technology and provides technical support for improving pig reproduction efficiency and optimizing reproduction quality with its excellent effectiveness and reliable safety. It is expected to drive the entire pig reproduction industry to a new level of development.
Batch production has been widely used in domestic and foreign pig farming enterprises, which can effectively improve production efficiency and economic benefits. During the batch production process, equine chorionic gonadotropin (eCG, also known as PMSG) extracted from pregnant mare serum is used to promote synchronized estrus in pig herds. However, there are many drawbacks to extracted products, such as limited raw material sources, the risk of disease transmission, instability between product batches, and animal welfare issues. Therefore, it is necessary to develop more excellent products for application in sow reproduction. This study used recombinant protein fusion technology to fuse porcine follicle-stimulating hormone (pFSH) with porcine Fc fragment, and developed the recombinant long-acting porcine FSH product. The recombinant long-acting FSH fusion protein was expressed in vitro using the CHO cell expression platform. A series of in vivo and in vitro experiments in this study proved that the recombinant protein has high biological activity, and pharmacokinetic detection was carried out in rats and the target animal sows, proving the long-acting nature of the fusion protein.
The blood drug concentration of the recombinant FSH fusion protein in sows after a single treatment is shown in the figure above.
The FSH and Fc fragments of the recombinant fusion protein developed in this study are of porcine origin, and are secreted and expressed in vitro through CHO cells, so there is no problem of limited production due to raw materials; through strict quality control, there is no problem of batch differences or the risk of disease transmission; the entire production process is completed in vitro, so there is no animal welfare issue. More importantly, the recombinant fusion protein developed in this study has strong molecular biological activity and high protein expression, which can effectively reduce production costs and thus reduce the end-use costs.
In conclusion, the recombinant long-acting FSH fusion protein has high biological activity and a long half-life, and the product has the advantages of higher safety, better quality, and lower cost. It solves the pain points and difficulties of using extracted products in agriculture and has the potential to become an effective and novel product for synchronized estrus in pig herds. This study was guided and assisted by Professor Cao Xingyuan's team from the College of Veterinary Medicine, China Agricultural University, and Professor Zhang Hua's team from the School of Life Sciences, and received strong support from the national "14th Five-Year" key research and development plan project "Upgrading of Precision Reproduction Regulation Technology and New Product Development for Pig Batch Production".
This research achievement is a vivid practice of interpreting the new quality productivity in the field of agricultural biopharmaceuticals. VJTBio continues to deeply cultivate in the track of animal protein innovation drugs, has built a complete technical matrix, and has accumulated deep technical barriers and rich practical experience. Standing at the forefront of the 100 billion animal protein drug market, VJTBio is writing a new chapter of Chinese creation in the field of life sciences with its continuous breakthroughs in "bottleneck" technology research and development.